‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the Bio CAPTURE network-Reference-Cited by-同舟云学术

‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the Bio CAPTURE network

Published:2014-10-03 Issue:5 Volume:171 Page:1189-1196
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Reek J.M.P.A.¹,Zweegers J.¹,Kievit W.²,Otero M.E.¹,Lümig P.P.M.¹,Driessen R.J.B.¹,Ossenkoppele P.M.³,Njoo M.D.³,Mommers J.M.⁴,Koetsier M.I.A.⁵,Arnold W.P.⁶,Sybrandy‐Fleuren B.A.M.⁷,Kuijpers A.L.A.⁸,Andriessen M.P.M.⁹,Kerkhof P.C.M.¹,Seyger M.M.B.¹,Jong E.M.G.J.¹

Affiliation:

1. Department of Dermatology Radboud University Medical Center Nijmegen the Netherlands

2. Department for Health Evidence Radboud University Medical Center Nijmegen the Netherlands

3. Department of Dermatology Hospital Group Twente (ZGT) Almelo/Hengelo the Netherlands

4. Department of Dermatology St. Anna Hospital, Ziekenhuis Geldrop the Netherlands

5. Department of Dermatology Gelre Hospital Apeldoorn the Netherlands

6. Department of Dermatology Gelderse Vallei Hospital (ZGV) Ede the Netherlands

7. Department of Dermatology Slingeland Hospital Doetinchem the Netherlands

8. Department of Dermatology Máxima Medical Center (MMC) Eindhoven/Veldhoven the Netherlands

9. Department of Dermatology Jeroen Bosch Hospital (JBZ) ’s‐Hertogenbosch the Netherlands

Funder

University Medical Centre St Radboud Foundation

Pfizer

Janssen

AbbVie

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.13087

Reference39 articles.

1. Transmembrane TNF- : structure, function and interaction with anti-TNF agents

2. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab

3. Long‐term safety and efficacy of etanercept in patients with psoriasis: an open‐label study;Leonardi C;J Drugs Dermatol,2010

4. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis

5. Efficacy and safety of systemic treatments for moderate‐to‐severe psoriasis: meta‐analysis of randomized controlled trials

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment switching and associated economic outcomes in patients with plaque psoriasis treated with biologics: A retrospective analysis of German claims data 2016−2021;JEADV Clinical Practice;2024-08-27

2. Drug survival for biologics in psoriasis patients: real world evidence for Greece during the period 2016-2020;Clinical and Experimental Dermatology;2024-07-06

3. The relationship between TNF-α, IL-1, IL-12, IL-17, IL-23, IL-36 expression and treatment response in psoriasis histopathologically and immunohistochemically;Cutaneous and Ocular Toxicology;2024-07-02

4. [Translated article] Comparing the Use of Topical Therapy Along with Anti-IL-17 and Anti-IL-23 to Treat Moderate-to-Severe Psoriasis in the Routine Clinical Practice;Actas Dermo-Sifiliográficas;2024-07

5. Comparación del uso de la terapia tópica combinada con anti-interleucina-17 y anti-interleucina-23 en la psoriasis moderada grave en la práctica clínica;Actas Dermo-Sifiliográficas;2024-07